Drug Type Small molecule drug |
Synonyms 乙酰克里定, 醋克立定, LNZ100 + [2] |
Target |
Action agonists |
Mechanism mAChRs agonists(Muscarinic acetylcholine receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |
Molecular FormulaC9H15NO2 |
InChIKeyWRJPSSPFHGNBMG-UHFFFAOYSA-N |
CAS Registry827-61-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Aceclidine |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Presbyopia | NDA/BLA | United States | 12 Aug 2024 |
Phase 3 | 300 | idbigxlagp(slttloiabf) = jvdorxblte mtblgkypzk (mvhkfmxswv ) Met View more | Positive | 28 Oct 2024 | |||
Placebo | idbigxlagp(slttloiabf) = htwigmctnx mtblgkypzk (mvhkfmxswv ) Met View more | ||||||
Phase 3 | - | mzucgkmjip(cvlsvvvvrs) = imbgeznzsv tqdzszsdvk (nhaaqvkesy ) Met | Positive | 13 Aug 2024 |